Story

Intel Options Market Pricing 11% Swing on July 23 Earnings Report

ENTHMSVIIDZHZH-TWJAKOHI
Jul 16, 20261 min read
Intel Options Market Pricing 11% Swing on July 23 Earnings Report

Summary

Options data indicates traders are expecting an 11% move in Intel's stock following its July 23 earnings. An analysis of the past eight reports shows the stock's actual reaction has exceeded market expectations half of the time.

Text size
Background

Options traders are bracing for a significant move in Intel Corp. (NASDAQ:INTC) shares following its upcoming earnings report, with market data indicating a potential swing of 11%. The semiconductor giant is scheduled to release its financial results on July 23 after the market close.

What the Options Market Is Pricing In

The anticipated 11% move is the options-implied volatility, a metric derived from trading activity in puts and calls that reflects investor expectations for the stock's price fluctuation. According to data compiled by Bloomberg, this figure represents the market's consensus on the magnitude of the post-earnings move, whether positive or negative.

This level of implied volatility highlights the market's uncertainty and anticipation surrounding Intel's performance, forward guidance, and commentary on the competitive landscape in the chip industry.

A History of Exceeding Expectations

Sample IUX Markets – In-articleAd

A review of Intel's recent history shows a pattern of post-earnings volatility that has often been more dramatic than the options market predicted. The stock's actual move has surpassed the implied swing in four of the past eight earnings announcements.

This track record suggests a significant event risk for investors and that the current 11% implied move could prove conservative. Notable past reactions include:

  • April 2026: Shares surged 27.1%, nearly triple the 9.3% move that options had priced in.
  • January 2025: The stock dropped 11.1%, exceeding the 9.3% implied decline.
  • August 2024: A significant earnings miss led to a 32.2% plunge, more than four times the 7.5% move anticipated by the options market.

Read next

More on Stocks
Shenzhen-Listed Jingxin Pharmaceutical Refiles for Hong Kong IPO

Stocks

Shenzhen-Listed Jingxin Pharmaceutical Refiles for Hong Kong IPO

Sep 20, 2026

Zhejiang Jingxin Pharmaceutical Co., Ltd. (002020.SZ) has resubmitted its application for a main board listing on the Hong Kong Stock Exchange, aiming to secure a dual listing to access international capital. The company specializes in drugs for central nervous system and cardiovascular diseases.

Back to latest news

LATEST